Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,889,191

« Back to Dashboard

Which drugs does patent 8,889,191 protect, and when does it expire?


Patent 8,889,191 protects TROKENDI XR and is included in one NDA. There have been two Paragraph IV challenges on Trokendi XR.

This patent has eleven patent family members in eight countries.

Summary for Patent: 8,889,191

Title:Sustained-release formulations of topiramate
Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Inventor(s): Liang; Likan (Boyds, MD), Wang; Hua (Clarksville, MD), Bhatt; Padmanabh P. (Rockville, MD), Vieira; Michael L. (Gaithersburg, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:12/926,936
Patent Claim Types:
see list of patent claims
Use; Formulation; Composition; Delivery; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-001Aug 16, 2013RXYesNo8,889,191► Subscribe TREATMENT OF EPILEPSY
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-002Aug 16, 2013RXYesNo8,889,191► Subscribe TREATMENT OF EPILEPSY
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-003Aug 16, 2013RXYesNo8,889,191► Subscribe TREATMENT OF EPILEPSY
Supernus Pharms
TROKENDI XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL201635-004Aug 16, 2013RXYesYes8,889,191► Subscribe TREATMENT OF EPILEPSY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,889,191

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,555,004Sustained-release formulations of topiramate► Subscribe
8,663,683Sustained-release formulations of topiramate► Subscribe
8,877,248Sustained-release formulations of topiramate► Subscribe
8,298,576Sustained-release formulations of topiramate► Subscribe
9,549,940Sustained-release formulations of topiramate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,889,191

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2007319141► Subscribe
Canada2618240► Subscribe
Germany07870164► Subscribe
European Patent Office1973528► Subscribe
European Patent Office2394643► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot